As the number of cases outside Africa approaches 800, governments are scrambling for a limited pool of vaccines and treatments with unclear effectiveness.
Tag: Emergent BioSolutions Inc
F.D.A. Gives Approval for Emergent Vaccine Plant in Baltimore to Reopen
After a two-day inspection, the F.D.A. said operations could start again at the Emergent BioSolutions site where Johnson & Johnson doses were contaminated.
White House to Send 3 Million Doses of J&J Vaccine to Brazil
The shipment is part of President Biden’s pledge to deliver 80 million doses overseas by the end of June.
High Hopes for Johnson & Johnson’s Covid Vaccine Have Fizzled in the U.S.
Production problems and a brief pause on its use kept the one-dose vaccine from becoming the game changer that health officials across the country believed it would be.
FDA Details Failures at Baltimore Plant That Spoiled Vaccine Doses
The F.D.A. advised Johnson & Johnson on Friday that it should throw out the equivalent of 60 million doses produced at the Baltimore plant.
Canada Rejects 300,000 Doses of J&J Vaccine Made in U.S.
The Canadian regulator also banned the use of all products made at Emergent BioSolutions’ plant in Baltimore until it conducts an on-site inspection.
U.S. Covid Vaccine Donations Will Go to ‘Wide Range’ of Nations
Latin America, South and Southeast Asia and Africa will be among the recipients of an initial 25 million excess doses that the Biden administration is sharing this month.
First U.S. Vaccine Donations Will Go to ‘Wide Range’ of Nations in Need
Latin America, South and Southeast Asia and Africa will be among the recipients of an initial 25 million excess doses that the Biden administration is sharing this month.
Emergent, Which Ruined Vaccine Doses, Gave Its Top Executives Bonuses
The government has so far paid Emergent BioSolutions $271 million, even though American regulators have yet to clear a single dose of vaccine produced at its manufacturing plant in Baltimore.
Emergent, Which Ruined Vaccine Doses, Gave Its Top Executives Bonuses
The government has so far paid Emergent BioSolutions $271 million, even though American regulators have yet to clear a single dose of vaccine produced at its manufacturing plant in Baltimore.